BCV
AMLX icon

Banque Cantonale Vaudoise’s Amylyx Pharmaceuticals AMLX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,900
Closed -$11K – 757
2024
Q2 		$11K Hold
5,900
– – ﹤0.01% 932
2024
Q1 		$17K Buy
+5,900
New +$77.2K ﹤0.01% 895

Other funds holding AMLX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Banque Cantonale Vaudoise's AMLX Position: Q3 2024 in Review

Banque Cantonale Vaudoise sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2024, closing a stake of 5,900 shares — an estimated $11K sold.

Banque Cantonale Vaudoise first reported a position in AMLX in Q1 2024 and held it in 2 quarters. The position peaked at $17K in Q1 2024. 110 funds tracked by Wall St. Rank hold AMLX as of Q3 2024.

  • Banque Cantonale Vaudoise reported no remaining Amylyx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 5,900 Amylyx Pharmaceuticals shares in Q3 2024, an estimated $11K.
  • Banque Cantonale Vaudoise first reported a position in Amylyx Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Banque Cantonale Vaudoise's Amylyx Pharmaceuticals position peaked at $17K in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2024.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2024, filed 8 Nov 2024.